Related Experiment Video
Updated: Feb 16, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells
Chao Dong1,2, Runxiang Yang2, Hongjian Li3,4
1Biomedical Engineering Research Center, Kunming Medical University, Kunming, Yunnan, China.
Abstract:
The phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway plays a pivotal role in many cellular processes, including the proliferation, survival and differentiation of lung cancer cells. Thus, PI3K is a promising therapeutic target for lung cancer treatment. In this study, we applied free and open-source protein-ligand docking software, screened 3167 FDA-approved small molecules, and identified putative PI3Kα inhibitors. Among them, econazole nitrate, an antifungal agent, exhibited the highest activity in decreasing cell viability in pathological types of NSCLC cell lines, including H661 (large cell lung cancer) and A549 (adenocarcinoma). Econazole decreased the protein levels of p-AKT and Bcl-2, but had no effect on the phosphorylation level of ERK. It inhibited cell growth and promote apoptosis in a dose-dependent manner. Furthermore, the combination of econazole and cisplatin exhibited additive and synergistic effects in the H661 and A549 lung cancer cell lines, respectively. Finally, we demonstrated that econazole significantly suppressed A549 tumor growth in nude mice. Our findings suggest that econazole is a new PI3K inhibitor and a potential drug that can be used in lung cancer treatment alone or in combination with cisplatin.
Insights
Econazole, an antifungal drug, shows potential as a new PI3K inhibitor for lung cancer treatment. It effectively reduced cancer cell viability and tumor growth, both alone and with cisplatin.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The phosphatidylinositol-3-kinase (PI3K)/AKT pathway is crucial for lung cancer cell proliferation and survival.
- Targeting PI3K offers a promising therapeutic strategy for lung cancer.
Purpose of the Study:
- To identify novel PI3K inhibitors from FDA-approved small molecules.
- To evaluate the efficacy of econazole as a PI3K inhibitor in non-small cell lung cancer (NSCLC).
Main Methods:
- Utilized free and open-source protein-ligand docking software for screening.
- Screened 3167 FDA-approved small molecules for PI3Kα inhibitory activity.
- Assessed econazole's effects on NSCLC cell lines (H661, A549) and in vivo tumor models.
Main Results:
- Econazole nitrate demonstrated significant activity in reducing NSCLC cell viability.
- Econazole decreased p-AKT and Bcl-2 protein levels, promoting apoptosis and inhibiting cell growth.
- Combination therapy with cisplatin showed additive/synergistic effects; econazole suppressed tumor growth in mice.
Conclusions:
- Econazole functions as a novel PI3K inhibitor with anti-lung cancer properties.
- Econazole presents potential as a therapeutic agent for lung cancer, either as a monotherapy or in combination with cisplatin.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The Intrinsic Apoptotic Pathway
Inhibition of Cdk Activity